plan from the application of reference pricing of ACE inhibitors to be $6 700 000 in the first
year alone. This estimate is substantially larger than those found by Grootendorst and …

The role of patient income levels, although extremely important, cannot be inferred from the
analysis of Schneeweiss and associates. 3 This is so both because the entire range of …

Bob Nakagawa and Rick Hudson suggest that captopril was the ACE inhibitor of choice in
hypertension at the time of our study and that patients in hospitals might have been …

If an existing drug reduces cholesterol by 26% and a new one by 29%, would that make any
difference to you? Not if you are a German public health official, a Massachusetts state …

The public reproach over the price of Mylan's lifesaving drug EpiPen is the latest imbroglio in
a much broader debate over drug costs. At issue is the rising list price on drugs. But as …

Last week, to great fanfare and much media attention across the country, the Canadian
Medical Association Journal announced the publication of a new study trumpeting the great …

Objectives: The assignment of prices or costs to pharmaceuticals can be crucial to results
and conclusions that are derived from pharmacoeconomic cost effectiveness analyses …

Last May, the former federal Health Minister Jane Philpott announced proposed changes to
the Patented Medicine Prices Review Board (PMPRB) designed" to protect Canadians from …

THE ISSUE OF PRESCRIPTION DRUG BENEFITS IS BEING HOTLY debated in the United
States. We can be sure that cost-conscious insurance organizations, both governmental and …

Background: Reference-based pricing is a cost-containment policy applied to prescription
drugs that are in the same class and deemed to be therapeutically equivalent. Recent …